Aviado · Research
Longevity Daily
Sunday, November 22, 2026
Listen
Today's Brief
Brain health is today's dominant theme, anchored by MIT's finding that the brain's nightly waste-clearing mechanism measurably breaks down with age — the kind of mechanistic link between sleep and dementia risk that makes optimizing sleep non-negotiable. New mouse research on FGF13 and astrocyte function adds a credible therapeutic target, while a deep dive into APOE ε4 management shows lifestyle programs can meaningfully shift genetic risk. Aviado Research dissects astragalus polysaccharides' reliable IL-6/IL-10 reset, and a rare honest audit in Herz draws the line between nutritional interventions that actually extend cardiovascular healthspan and those that remain wishful thinking.
10 stories1 peer-reviewed1 Aviado original
Cognitive Health & Neuroprotection
MIT Finds the Brain's Nightly Cleanup System Fails With Age — And That May Drive Dementia
MIT researchers have confirmed what many aging adults already suspect: the process responsible for flushing metabolic waste from the brain during sleep is significantly and commonly impaired in older adults — not an edge case, but a measurable biological failure. This glymphatic-style clearance system normally sweeps away amyloid, tau, and other toxic proteins during deep sleep, but aging disrupts its efficiency in ways that likely accelerate neurodegeneration. The finding reframes sleep optimization as a frontline neurological intervention, not just a lifestyle preference. If your sleep quality has declined with age, this study gives you a mechanistic reason to treat restoration of deep, restorative sleep as a clinical priority.
Read more →Restoring One Gene in Brain Support Cells Slows Cognitive Aging in Mice
Researchers found that overexpressing FGF13 — a gene whose activity naturally declines with age — in astrocytes, the brain's primary support cells, preserved cognitive function and slowed memory deterioration in aging mice. Restoring FGF13 to youthful expression levels appears to maintain astrocyte health in a way that meaningfully protects against age-related cognitive decline. This is mouse research, but it adds a credible and actionable target to the increasingly mapped landscape of brain aging biology.
Read more →If You Carry the APOE ε4 Gene, Lifestyle Programs Can Still Shift Your Brain's Trajectory
Carrying the APOE ε4 allele roughly triples lifetime Alzheimer's risk, but this analysis makes clear the risk is modifiable: comprehensive lifestyle programs combining exercise, diet, cognitive training, and social engagement show the clearest and most durable benefits for ε4 carriers. Standalone brain-training apps, by contrast, show reliable gains mainly on the tasks practiced, with weaker evidence for long-term dementia prevention — the meaningful signal lives in multidomain programs. If you know your APOE status and carry ε4, a structured multidomain lifestyle protocol is your most evidence-backed protective tool.
Read more →Supplements & Compounds
Astragalus Polysaccharides Reset Your Inflammatory Balance — Here's the Dose That Works
Meta-analyses of over 6,000 participants show astragalus polysaccharides reliably lower pro-inflammatory IL-6 by 22–29 pg/mL while boosting protective IL-10 — and the effect holds regardless of starting inflammation level, age, or health status. The cytokine rebalancing takes 4–12 weeks and correlates with real-world improvements in cholesterol, blood sugar stability, and quality of life scores. For supplementation, look for extracts specifying polysaccharide content (300–1,200 mg daily) rather than generic root powders, and give it at least 8 weeks before evaluating results.
Read the full Aviado analysis →Vitamin D May Lower Dementia Risk — But Only If You're Actually Deficient
Growing evidence links vitamin D to neuroprotective processes that may lower dementia risk, but current human research is limited — and the benefit appears concentrated in people who are genuinely deficient, not those supplementing on top of adequate levels. High-dose supplementation in already-replete individuals is unlikely to deliver the dramatic brain benefits sometimes promoted. If you haven't checked your 25-OH vitamin D level recently, that's the logical first step before spending on supplements.
Read more →Research & Papers
What Nutrition Science Actually Proves About Longevity (And What It Doesn't)
A rigorous narrative review in Herz draws a sharp line between nutritional interventions with solid cardiovascular longevity evidence — Mediterranean diet, DASH, sodium reduction, GLP-1 drug-driven weight loss — and those that remain largely unproven, including isolated supplements, intermittent fasting's specific longevity effects, and caloric restriction's impact on human mortality. The authors are notably candid: randomized caloric restriction has so far only modestly slowed epigenetic aging clocks and has not demonstrated mortality benefit in humans. If you're investing in longevity supplements based primarily on surrogate biomarker data, this peer-reviewed audit is a useful reality check.
Read more →Senolytics Clear Zombie Cells in Humans, New Evidence Confirms
New analysis confirms that senolytic compounds — designed to selectively eliminate senescent 'zombie' cells — can measurably reduce biomarkers of cellular senescence in human participants, an important step beyond the mostly animal-based evidence that has dominated the field. The most studied combination remains dasatinib and quercetin, though dose optimization and long-term outcome trials are still needed. This human-level validation is an encouraging signal that senolytic strategies belong in serious longevity conversations beyond the lab.
Read more →Lifestyle & Nutrition
Bryan Johnson Spends $2 Million a Year on Longevity. The Effective Part Is Free.
A close read of Bryan Johnson's Blueprint protocol finds that the interventions with the strongest evidence base — a consistent early sleep schedule, daily exercise, and a whole-food diet — cost nothing. The $2M/year in advanced diagnostics, experimental therapies, and continuous tracking generates interesting data, but the incremental longevity benefit over the free behaviors remains unproven. The lesson for everyone else: disciplined consistency in the basics almost certainly compounds more reliably than any exotic biohacking stack.
Read more →Muscle Strength, Not Size, Is the Longevity Metric That Actually Matters
Exercise physiologists including McMaster's Stuart Phillips and orthopedic surgeon Vonda Wright clarify that grip strength and functional strength measures are more strongly and consistently linked to longevity outcomes than muscle mass or size alone. This matters for anyone training primarily for hypertrophy: bulk without functional strength may be missing the longevity signal entirely. The practical takeaway is to prioritize compound movements — squats, deadlifts, loaded carries — that build functional capacity rather than chasing size metrics.
Read more →Industry & Policy
One Biotech CEO Is Running the Clinical Trial That Could Define What 'Healthy Aging' Means
Cambrian Biopharma CEO James Peyer makes the case for mTOR inhibitors as the most promising pharmaceutical class for demonstrably improving intrinsic capacity — ARPA-H's composite measure of healthy aging — in clinical trials of healthy older adults, not just disease populations. The company has partnered with ARPA-H's PROSPR program to run what could be among the first rigorous longevity drug trials in healthy elderly people. If the trial succeeds, it sets a regulatory template for how every future longevity pharmaceutical gets evaluated.
Read more →